Trial Profile
A Phase 1a study to investigate the immunogenic potential of PIN-2 administered intravenously to patients with advanced solid tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 18 Apr 2022
Price :
$35
*
At a glance
- Drugs PIN 2 (Primary)
- Indications Solid tumours
- Focus Biomarker; First in man; Pharmacodynamics; Pharmacokinetics; Proof of concept
- Sponsors PIN Pharma Inc
- 04 Jun 2019 Results assessing immune activation and safety of PIN- 2 administered intravenously to patients with advanced solid tumors, were presented at the 55th Annual Meeting of the American Society of Clinical Oncology.
- 06 May 2019 According to a PIN Pharma Inc media release, data from this trial will be presented at the 55th Annual meeting of ASCO in Chicago on June 1 2019.
- 02 Jan 2019 According to a PIN Pharma Inc media release, this study is conducted by PIN Pharma's wholly owned Australian subsidiary, PIN Pharma Pty Ltd.